High-potency Antihæmophilic Factor Concentrate prepared from Cryoglobulin Precipitate

@article{Pool1964HighpotencyAF,
  title={High-potency Antih{\ae}mophilic Factor Concentrate prepared from Cryoglobulin Precipitate},
  author={J. Pool and E. Hershgold and A. Pappenhagen},
  journal={Nature},
  year={1964},
  volume={203},
  pages={312-312}
}
INVESTIGATIONS made to determine the causes of loss of antihæmophilic factor (AHF) during the Blombäck process1 for preparing AHF-rich fibrinogen from large volumes of plasma have revealed that when the starting material is frozen plasma instead of fresh plasma there is a presumed liability which can be converted to an advantage. 

Topics from this paper

Enhanced Yield of Antihemophilic Factor and von Willebrand Factor by Cryoprecipitation with Polyethylene Glycol 1
Abstract. A procedure involving cryoprecipitation of human plasma in the presence of polyethylene glycol results in consistently higher yields of antihemophilic factor and von Willebrand factor thanExpand
Preparation of Factor VIII Concentrates by Cryoprecipitate Sedimentation
TLDR
A new method for factor VIII concentrate preparation is proposed, which is the collection of cryoprecipitate after sedimentation at 4 C in a jacketed glass vessel and is comparable to other processes. Expand
Cryoprecipitate: an outmoded treatment?
TLDR
The most common use of cryoprecipitate is fibr inogen replacement in patients with acquired hypofibrinogenaemia and bleeding. Expand
Concentrated Antihemophilic Factor (AHF) from Outdated Blood
TLDR
Following intravenous injection into hemophilic patients, high levels of circulating AHF, in excess of 60 per cent of normal, have been achieved without causing circulatory overload. Expand
Human Factor VIII Prepared by Cryoprecipitation 1
TLDR
When previously frozen normal human plasma is thawed a t 4"C, about 3% of the plasma proteins remain insoluble, suggesting that partially purified factor VIII was insoluble in the cold state. Expand
Cryoprecipitate: the current state of knowledge.
TLDR
Despite 45 years of the use of this product, there is a lot to learn regarding the optimal use of cryoprecipitate and the best method of pooling before transfusion has not been thoroughly investigated. Expand
Progress in large‐scale purification of factor VIII/von Willebrand factor concentrates using ion‐exchange chromatography
TLDR
This work investigated and optimized the parameters of a chromatographic process suitable for industrial scale to obtain a highly purified factor VIII (FVIII)/von Willebrand factor (VWF) concentrate. Expand
Studies on the purification of antihemophilic factor (factor VIII). II. Separation of partially purified antihemophilic factor by gel filtration of plasma.
TLDR
A high degree of purification of antihemophilic factor was achieved by filtration of chylomicronpoor human plasma through columns of agarose, and similar fractions of plasma prepared from the blood of patients with classic hemophilia, von Willebrand's disease, or a circulating anticoagulant directed against antihemophile factor contained, on the average, somewhat less protein than normal plasma. Expand
THE TREATMENT OF HAEMOPHILIA BY AHG‐RICH PLASMA CRYOPRECIPITATE
TLDR
The proportion of patients showing a chromosome abnormality closely follows that of Jacobs ct alii (1961), in their study of chromosome abnormalities in 32 cases of primary amenorrhrea. Expand
USE OF RECOMBINANT HUMAN COAGULATION FACTOR VIII ( ADVATE ) TO TREAT HAEMOPHILIA A
 Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by deficient or missing factor VIII, a major clotting protein. Thus, it is the majorityExpand
...
1
2
3
4
5
...